Search results for " antibody fragments"
Article
Capture of Bispecific Antibodies and Removal of Product-Related Impurities
The biotherapeutics pipeline is becoming increasingly diverse as antibody variants such as bispecifics, conjugates, and fragments move through preclinical stages to commercial manufacturin…
Article
Efficient Cleaning-In-Place Methods for Protein-Based Antibody Affinity Chromatography Resins
This whitepaper discusses cleaning of affinity resins intended for use in the purification of monoclonal antibodies and antibody fragments, for example, Fab fragments. Various cleaning strategies and …
Webcast
Biotech Makers: Solving challenges in process development of a diversifying antibody pipeline
The therapeutic pipeline for antibodies continues to diversify into new modalities including bi-specific, tri-specific, antibody fragments and domain antibodies which bring new challenges to process…
Article
Antibody purification quiz
How well do you know antibodies and antibody purification?
Test your knowledge and gain insights in the purification of antibody variants – bsAbs, Fab, dAbs.
Article
Antibody Production Workflow
Explore the workflow here >>
Antibody-based therapies have evolved beyond monoclonal antibodies (mAbs) to include bispecific antibodies, antibody fragments, antibody-drug conjugates (ADCs), and m…
Article
Single-Step, Protein A Chromatography Process for Bispecific Antibodies in Early Screening
A single-step downstream process using protein A chromatography to purify a bispecific antibody (BsAb) in early screening has been successfully developed to replace an existing three-step process. T…
Article
A Platform Approach for the Purification of Domain Antibodies (Dabs)
This Application note describes a three-step purification process of a domain antibody (Dab) expressed in the periplasm of E. coli. First, a capture step using Capto™ L was used to reduce E. coli host…
Article
Modeling the Degradation of mAb Therapeutics
Modeling the Degradation of mAb Therapeutics
Kinetic models can be used to study aggregation and fragmentation to help ensure stability.
By Anurag S. Rathore, Rohit Bansal
…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
In the future, mAbs may represent a smaller percentage of the pipeline as portfolios concentrate more on development of antibody fragments, nanobodies, biosimilar protein therapeutics, conjugated prot…
Article
Analysis of Glycosylation in Biosimilars
A step-wise process is used to characterize glycans and understand the functioning of a molecule for biosimilar development.
The structures of protein drugs such as monoclonal antibodies are mad…